医学
膈式呼吸
外科
肝移植
肝切除术
振膜(声学)
脾切除术
下腔静脉
门脉高压
放射科
肝功能
阿苯达唑
门静脉造影
包虫病
移植
泡状棘球蚴病
治疗
外科手术组
门诊部
肝功能检查
标识
DOI:10.1097/lvt.0000000000000891
摘要
Background: Alveolar echinococcosis is a rare but aggressive parasitic disease, and liver transplantation (LT) is considered in selected patients with unresectable hepatic involvement. The last systematic review published in 2018 reported 150 LT cases over 30 years. With advances in surgical technique, imaging, and immunosuppression, the number and complexity of LT procedures for this indication have increased, warranting an updated analysis. Purpose: To conduct a systematic review of liver transplantation for hepatic alveolar echinococcosis and to update previously published outcomes. Method: A systematic literature search was performed in PubMed, ScienceDirect, and Google Scholar following PRISMA guidelines and registered in PROSPERO. Articles published between 2017 and 2025 were included. Extracted data included patient characteristics, prior surgeries, vascular invasion, perioperative antiparasitic therapy, recurrence, and survival outcomes. Result(s): Twenty-three studies reporting 106 LT procedures were included. The mean patient age was 38 years. Prior liver resection had been performed in 45% of patients, and Budd– Chiari syndrome was reported in 23%. Vascular invasion was present in most cases. Living donor LT accounted for 56% of procedures. Albendazole therapy was administered preoperatively in 58% and postoperatively in 87% of patients. Recurrence occurred in 14% of reported cases. One-year and five-year survival rates were 94% and 86%, respectively. Conclusion(s): According to the present data, liver transplantation is a suitable treatment method for unresectable liver echinococcosis in selected patients. The outcomes are comparable to patients who underwent liver transplantation due to liver cirrhosis and other indications.
科研通智能强力驱动
Strongly Powered by AbleSci AI